Dupixent Lymphoma Lawsuit Alleges Atopic Dermatitis Drug Led to Mycosis Fungoides Diagnosis

Juliana Perez, a California resident, filed suit on August 12 in U.S. District Court for the District of New Jersey against Sanofi-Aventis, Regeneron Pharmaceuticals, and Genzyme Corporation over the immunosuppressant drug Dupixent. Perez alleges she developed mycosis fungoides, a rare form of cutaneous T-cell lymphoma (CTCL), after using Dupixent for less than six months.

The complaint asserts that the manufacturers were aware of an increased cancer risk from Dupixent but prioritized profits over patient safety and failed to warn physicians and patients of this potential harm. Perez claims she now faces the prospect of lifelong monitoring and cancer treatment as a result of using the drug.

Dupixent received initial FDA approval in 2017 for atopic dermatitis (eczema) and has since been approved for additional indications including asthma, COPD, and other conditions linked to immune system dysfunction. While the manufacturers have maintained the drug's safety profile, a series of adverse events, particularly CTCL diagnoses, have been linked to Dupixent use in recent years.

This is a curated brief from the PlaintiffWire news desk. Read the original report at AboutLawsuits.